3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Glioblastoma
39
Brain Neoplasms
17
Astrocytoma
16
Central Nervous System Neoplasms
9
Oligodendroglioma
8
Gliosarcoma
8
Melanoma
7
Glioma
7
Neoplasms
5
Recurrence
4
Neoplasm Metastasis
3
Neuroblastoma
2
Ganglioneuroblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Choroid Plexus Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Sarcoma, Ewing
1
Sarcoma
1
Rhabdoid Tumor
1
Rare Diseases
1
Optic Nerve Glioma
1
Neurotoxicity Syndromes
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Neuroepithelial
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Melanoma, Cutaneous Malignant
1
Interventions
pasireotide
2
Octreotide
2
Everolimus
2
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Leucovorin
1
Folfox protocol
1
Fluorouracil
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gastro-enteropancreatic neuroendocrine tumor
×
Temozolomide
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled